Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK653m

    Last close

    SEK14.10

    ▲ 1.50 (11.90%)

    VolitionRx

    MCap

    USD51m

    Last close

    USD0.60

    ▲ 0.05 (9.82%)

    Portobello SpA

    MCap

    EUR12m

    Last close

    EUR2.38

    ▲ 0.20 (9.17%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

OTC Markets Group (US: OTCM)

Last close As at 04/11/2024

55.78

▲ 0.74 (1.34%)

Market capitalisation

661m

Edison Investment Research is terminating coverage on OTC Markets Group. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Financials | Update

OTC Markets Group — Q122 – net income up 11%, but costs start to bite

Financials | Outlook

OTC Markets Group — Q421 was another beat, 2022 is more uncertain

Financials | Update

OTC Markets Group — Hitting it out of the ballpark

Financials | Update

OTC Markets Group — Revenue beat, positive business mix
Visit Website

Sector

Financials

Balance Sheet

Forecast net debt (US$m)

33.2

Forecast gearing ratio (%)

125

Share Price Performance

Financials

OTC Markets Group’s (OTCM’s) Q122 net income was up 11% y-o-y despite weaker financial markets trading volume and prices. Corporate services (+51% y-o-y) and market data licensing (+9% y-o-y) revenue was as resilient as expected and compensated for the 47% decline in OTC Link revenue. However, operating expenses rose by 12% due to rising staff compensation and IT. OTCM purchased Blue Sky Data for $12m cash in May 2022, allowing OTCM to improve its value proposition and expand its subscriber base. We maintain our assumption that markets will remain choppy due to concerns about inflation and rising interest rates. We have cut our EPS forecasts for FY22 and FY23 by 19% and 17% respectively to reflect higher operating expense assumptions. We have cut our dividend forecasts by 20% but note that this could be conservative given OTCM’s strong balance sheet and cash flow generation.

Research

Outlook

Financials

OTC Markets Group — Q421 was another beat, 2022 is more uncertain

Update

Financials

OTC Markets Group — Hitting it out of the ballpark

Financials

Update

OTC Markets Group — Q122 – net income up 11%, but costs start to bite

Update

Financials

OTC Markets Group — Revenue beat, positive business mix

Update

Financials

OTC Markets Group — Long term focus remains as volumes spike

Update

Financials

OTC Markets Group — Focus remains on long-term value

Outlook

Financials

OTC Markets Group — A further estimate upgrade

Update

Financials

OTC Markets Group — Trading well and keeping its long-term focus

Update

Financials

OTC Markets Group — Staying on course

Update

Financials

OTC Markets Group — Keeping focus amid near-term uncertainty

edison tv

Financials

Executive interview – OTC Markets Group
View All

Thematics

View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free